# Abbott Laboratories (ABT)

**Sector**: Healthcare / Medical Devices
**Current Price**: $112.21
**Market Cap**: $195.3B
**52w Range**: $105 - $139 (19% below high)
**Last Updated**: 2026-02-23

---

## Thesis

Abbott is a diversified medical device and diagnostics company with durable competitive moats in hospital procurement relationships and FDA-cleared product lines. CEO Robert Ford's $2M personal buy at $107 is among the strongest insider conviction signals in the dataset — the highest-quality signal when the person buying has direct visibility into the product pipeline. Every valuation model in the toolkit shows meaningful upside from current levels, and the balance sheet (D/E 0.3) leaves room to withstand macro pressure.

---

## Fundamentals

| Metric | Value |
|--------|-------|
| P/E | 30.1 |
| P/B | 3.7 |
| Current Ratio | 1.6 |
| ROE | 13.0% |
| D/E | 0.3 |
| Operating Margin | 11.3% |
| Revenue Growth (YoY) | 4.4% |
| Earnings Growth (YoY) | -80.9% |
| Profit Margin | 14.7% |

Earnings decline of -80.9% is likely driven by one-time charges rather than structural deterioration — operating margin (11.3%) and profit margin (14.7%) remain positive, and revenue growth is intact at 4.4%.

---

## Insider Activity (180d)

| Person | Role | Amount | Price | Date (approx) |
|--------|------|--------|-------|----------------|
| Robert Ford | CEO | $2.0M | $107 | ~19 days ago |
| Daniel Starks | Director | $1.1M ($545K + $542K) | — | ~19 days ago |

- **Buys / Sells**: 3 / 1
- **Cluster size**: 2 insiders buying in close proximity
- **Total conviction**: $3.1M

CEO buying $2M at $107 with the stock now at $112 means he is already in-the-money. Cluster buying (CEO + board director simultaneously) is statistically more meaningful than a single isolated purchase.

---

## Valuation Models

| Model | Target | Upside |
|-------|--------|--------|
| GBM Opp 3y | $169 | +50.6% |
| GBM Opp 1y | $168 | +49.4% |
| RIM | $157 | +39.7% |
| GBM Lite 3y | $150 | +33.4% |
| GBM Lite 1y | $135 | +20.4% |

All five models are aligned — no model shows downside. The conservative GBM Lite 1y still implies +20% within a year.

**Opportunity Score**: 48.8
- Quality (Q): 67.6
- Value (V): 32.9
- Growth (G): 33.3
- Risk/Reward (R): 74.5
- Catalyst (C): 53.1

Risk/Reward (74.5) and Quality (67.6) are the two strongest sub-scores. Value (32.9) and Growth (33.3) are the drags — this is not a deep-value or high-growth story, it is a quality compounder at a premium.

---

## Bull Case

- CEO Robert Ford bought $2M personally at $107 — direct pipeline visibility makes this a high-conviction signal
- Low leverage (D/E 0.3) provides resilience and optionality for capital allocation
- Medical devices is a secular growth market; demographic tailwinds from aging populations are structural
- Every valuation model shows upside, with a central case around +40-50% over 3 years
- Defensive healthcare positioning limits downside in risk-off environments

## Bear Case

- P/E of 30x is elevated relative to ~4% revenue growth — multiple compression is a real risk if growth disappoints
- Earnings declined -80.9% YoY; even if one-time in nature, it erodes short-term EPS support for the valuation
- Operating margin (11.3%) is below med-tech peers like Medtronic (MDT) or Stryker (SYK), suggesting pricing power or cost structure is weaker
- Growth score of 33.3 is low — this is not a growth compounder, and paying 30x P/E for 4% revenue growth requires margin expansion to justify

---

## Key Risks

1. **Earnings quality**: The -80.9% earnings decline needs to be traced to specific charges (litigation, restructuring, impairment). If it recurs, the 30x P/E has no support.
2. **Multiple compression**: At 30x P/E with low growth, the stock is priced for perfection; any macro slowdown or guidance cut could re-rate it toward 22-25x.
3. **Competitive pressure in diagnostics**: Rapid testing revenues surged during COVID and have since normalized; recovery of that segment depends on new product cycles.
4. **Interest rate sensitivity**: High-P/E, low-growth stocks are vulnerable to rate increases; a hawkish Fed re-run could pressure the multiple.

---

## AI Disruption Assessment

**Risk level: Low**

Medical devices are physical products requiring FDA 510(k)/PMA approval, clinical validation, and embedded hospital procurement relationships. These are multi-year moats that AI cannot disintermediate in any near-term scenario.

If anything, AI is a tailwind for Abbott: AI-powered interpretation of rapid diagnostic results (e.g., accelerating point-of-care test reads, reducing false positives) could enhance product value and justify premium pricing. Abbott's diagnostics division (Alinity platform, BinaxNOW, etc.) is a natural candidate for AI-augmentation rather than displacement.

---

## Notes

- Analysis date: 2026-02-23
- Insider data window: 180 days as of analysis date
- Valuation models: GBM (Geometric Brownian Motion, Opportunity and Lite variants), RIM (Residual Income Model)
- Earnings growth figure (-80.9%) likely reflects one-time charges; requires verification against quarterly filings before sizing a position
